From: Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
ΔCosts | ΔQALYs | ICURs, $/QALY | |||||
---|---|---|---|---|---|---|---|
Values | B vs A | C vs A | B vs A | C vs A | B vs A | C vs A | |
Base case | $58,488 | $77,004 | $0.163 | $0.134 | $358,088 | $575,540 | |
Remission rate in responders | |||||||
Usual care | 0.054 | $58,049 | $76,557 | 0.181 | 0.151 | $320,893 | $505,803 |
0.238 | $58,937 | $77,446 | 0.146 | 0.117 | $402,860 | $663,307 | |
5 mg/kg infliximab | 0.174 | $57,360 | $76,880 | 0.121 | 0.100 | $476,059 | $768,537 |
0.378 | $59,592 | $77,143 | 0.203 | 0.166 | $293,330 | $464,724 | |
Remission rate in non-responders induced | |||||||
Adalimumab | 0.061 | $58,054 | $76,876 | 0.123 | 0.120 | $471,182 | $641,097 |
0.139 | $58,923 | $77,133 | 0.200 | 0.146 | $295,032 | $526,848 | |
Early IPAA | 0.108 | $72,853 | $95,814 | 0.254 | 0.215 | $286,943 | $446,029 |
0.475 | $47,476 | $61,931 | 0.104 | 0.082 | $457,710 | $753,220 | |
Utilities | |||||||
Remission | 0.720 | $58,499 | $77,007 | 0.111 | 0.087 | $527,236 | $889,227 |
0.858 | $58,499 | $77,007 | 0.214 | 0.180 | $273,081 | $428,676 | |
Surgical remission | 0.598 | $58,499 | $77,007 | 0.197 | 0.167 | $296,939 | $462,473 |
0.762 | $58,499 | $77,007 | 0.130 | 0.101 | $451,163 | $761,873 | |
Surgical complications | 0.399 | $58,499 | $77,007 | 0.185 | 0.155 | $316,155 | $497,122 |
0.580 | $58,499 | $77,007 | 0.142 | 0.113 | $412,327 | $681,998 |